Posts by Mourabit Halima

Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge, characterized by poor overall prognosis, limited effective treatment options, high unmet medical need, and suboptimal safety profiles. Innovative treatment strategies are urgently needed.

With the release of data from studies such as DESTINY-Breast09 (DB-09), antibody–drug conjugates (ADCs) are gaining increasing prominence in the first-line treatment of HER2-positive metastatic breast cancer (MBC). However, while the traditional THP regimen (trastuzumab + pertuzumab + taxane) remains firmly established as the guideline-preferred standard, the question remains: has the “era of ADC dominance” truly begun? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Leiping Wang from Fudan University Shanghai Cancer Center addressed this question. She emphasized that although ADCs have opened the door to first-line therapy with impressive progression-free survival (PFS) benefits, their full integration into clinical practice still requires further validation, particularly in the context of refined disease management and treatment sequencing.

On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan Cancer Hospital) as co–first authors. With a median follow-up of 45.5 months, the study demonstrated that first-line treatment with pyrotinib in combination with trastuzumab and docetaxel significantly improved overall survival (OS) in patients with HER2-positive metastatic breast cancer, reducing the risk of death by 26%. These findings establish a dual-targeted regimen that reflects a distinct “China-developed strategy” for first-line treatment in this population.

Precision testing is only as valuable as its timing. During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Hao Wang from Sichuan Cancer Hospital delivered a focused presentation on the optimal timing of endocrine-related molecular testing in patients with HR+/HER2– metastatic breast cancer.

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian Provincial Hospital to engage in an in-depth discussion on the evolution of ADCs, recent clinical advances, toxicity management, and future trends. Drawing on cutting-edge clinical data and real-world experience, the two experts offer valuable insights into efficacy optimization, toxicity management, frontline integration, combination strategies, and drug diversification.